QQ客服 官方微博 反馈留言

	Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy
	Li Zhanguo; Zhang Fengchun; Kay Jonathan; Fei Kaiyin; Han Chenglong; Zhuang Yanli; Wu Zhong; Hsia Elizabeth C
	2016
卷号	19期号:11页码:1143-1156
关键词	Asian anti-tumor necrosis factor biologics rheumatoid arthritis
ISSN号	1756-185X
DOI	10.1111/1756-185X.12723
URL标识	查看原文
收录类别	PUBMED
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6376042
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Li Zhanguo,Zhang Fengchun,Kay Jonathan,et al. Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy[J],2016,19(11):1143-1156.
APA	Li Zhanguo.,Zhang Fengchun.,Kay Jonathan.,Fei Kaiyin.,Han Chenglong.,...&Hsia Elizabeth C.(2016).Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy.,19(11),1143-1156.
MLA	Li Zhanguo,et al."Efficacy and safety results from a Phase 3, randomized, placebo-controlled trial of subcutaneous golimumab in Chinese patients with active rheumatoid arthritis despite methotrexate therapy".19.11(2016):1143-1156.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。